MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

Stopped Study closed for business reasons before patient recruitment was initiated.

Conditions

• Rheumatoid Arthritis

Interventions

• BIOLOGICAL: MabionCD20 (candidate biosimilar to rituximab)
• BIOLOGICAL: MabThera®
• BIOLOGICAL: Rituxan®

Sponsor

Mabion SA

Collaborators

• [object Object]